MedTrace Logo

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

NCT06686771 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-05-12

No results posted yet for this study

Summary

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs?

This study is being done to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as the care most people get for non-small cell lung cancer.

Conditions

Interventions

RADIATION

SBRT

Please refer to the current NCCN NSCLC guidelines for possible treatment options

OTHER

First or second-line standard of care therapy

Please refer to the current NCCN NSCLC guidelines for possible treatment options.

Sponsors & Collaborators

Principal Investigators

  • C. Jillian Tsai · University Health Network Princess Margaret Hospital, Toronto, ON Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-16
Primary Completion
2030-02-28
Completion
2030-12-31
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686771 on ClinicalTrials.gov